oral, brain-penetrant LRRK2 kinase inhibitor recapitulated LRRK2 lung tox. in model discovery details manuscript in preparation J. Pharmacol. Exp. Ther., Jan. 28, 2021 Merck & Co., Inc., Boston, MA